JP2018502922A - エボラウイルスワクチン接種のための方法および組成物 - Google Patents

エボラウイルスワクチン接種のための方法および組成物 Download PDF

Info

Publication number
JP2018502922A
JP2018502922A JP2017555422A JP2017555422A JP2018502922A JP 2018502922 A JP2018502922 A JP 2018502922A JP 2017555422 A JP2017555422 A JP 2017555422A JP 2017555422 A JP2017555422 A JP 2017555422A JP 2018502922 A JP2018502922 A JP 2018502922A
Authority
JP
Japan
Prior art keywords
ebola virus
virus antigen
seq
vector
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017555422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502922A5 (enExample
Inventor
フランク アール． ジョーンズ，
フランク アール． ジョーンズ，
エリザベス ガビッチ，
エリザベス ガビッチ，
Original Assignee
イーチュービクス コーポレイション
イーチュービクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーチュービクス コーポレイション, イーチュービクス コーポレイション filed Critical イーチュービクス コーポレイション
Publication of JP2018502922A publication Critical patent/JP2018502922A/ja
Publication of JP2018502922A5 publication Critical patent/JP2018502922A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017555422A 2015-01-09 2016-01-07 エボラウイルスワクチン接種のための方法および組成物 Pending JP2018502922A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101968P 2015-01-09 2015-01-09
US62/101,968 2015-01-09
PCT/US2016/012482 WO2016112188A1 (en) 2015-01-09 2016-01-07 Methods and compositions for ebola virus vaccination

Publications (2)

Publication Number Publication Date
JP2018502922A true JP2018502922A (ja) 2018-02-01
JP2018502922A5 JP2018502922A5 (enExample) 2019-02-14

Family

ID=56356425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017555422A Pending JP2018502922A (ja) 2015-01-09 2016-01-07 エボラウイルスワクチン接種のための方法および組成物

Country Status (9)

Country Link
US (1) US10695417B2 (enExample)
EP (1) EP3256140B1 (enExample)
JP (1) JP2018502922A (enExample)
KR (1) KR20170102002A (enExample)
CN (1) CN107530383A (enExample)
AU (1) AU2016205208A1 (enExample)
CA (1) CA2973109A1 (enExample)
ES (1) ES2795833T3 (enExample)
WO (1) WO2016112188A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023527261A (ja) * 2020-03-11 2023-06-28 イミュニティーバイオ、インコーポレイテッド Ｃｏｖｉｄ－１９の治療及びその方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
EP3484509A4 (en) * 2016-07-15 2020-03-25 Etubics Corporation COMPOSITIONS AND METHODS FOR VACCINATION AGAINST FLAVIVIRUS
CA3030451C (en) 2016-07-15 2023-09-05 Etubics Corporation Compositions and methods for alphavirus vaccination
WO2018039640A1 (en) * 2016-08-26 2018-03-01 The Broad Institute, Inc. Nucleic acid amplification assays for detection of pathogens
US12622961B2 (en) 2019-09-10 2026-05-12 The Penn State Research Foundation Lipopolysaccharide molecules for enhancing immune responses
US20210284716A1 (en) * 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
CN115244077B (zh) 2020-03-11 2025-04-29 南特细胞公司 蛋白质治疗剂
US20240327492A1 (en) 2021-07-29 2024-10-03 Nantcell, Inc. Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
EP4335870A1 (en) 2022-09-06 2024-03-13 NantCell, Inc. Peptide therapeutics against sars-cov-2 spike protein
JP2026515943A (ja) * 2023-05-04 2026-05-19 イミュニティバイオ，インコーポレーテッド アデノウイルスベクターで形質導入されたアフェレーシス産物
TW202548026A (zh) * 2024-05-16 2025-12-16 瑞士商輝凌國際中心公司 用於純化重組腺病毒載體之方法
US20260001951A1 (en) 2024-06-28 2026-01-01 Immunitybio, Inc. Anti-SLAMF7 Antibodies And Therapeutics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006479A2 (en) * 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
WO2014031178A1 (en) * 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
ATE421888T1 (de) 1997-08-13 2009-02-15 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
ES2217585T3 (es) 1997-10-10 2004-11-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
EP1447414B1 (en) 1997-10-10 2007-06-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Antagonist peptides of carcinoembryonic antigen (CEA)
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AU774076C (en) 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2002008436A2 (en) 2000-07-20 2002-01-31 Genstar Therapeutics Corporation Mini-adenoviral vector system for vaccination
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP1417353A4 (en) 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
US8236776B2 (en) 2002-04-09 2012-08-07 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
CN1548537B (zh) 2002-12-27 2010-05-05 深圳市源兴生物医药科技有限公司 疫苗制备方法和抗肿瘤疫苗
EP1622937A2 (en) 2003-05-05 2006-02-08 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Synthetic gene encoding human carcinoembryonic antigen and uses thereof
US8207314B2 (en) 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
EP1649020B1 (en) 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
US9592284B2 (en) * 2004-04-28 2017-03-14 The Trustees Of The University Of Pennsylvania Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost
US8012468B2 (en) 2004-06-11 2011-09-06 Catholic Universtiy Industry Academic Cooperation Foundation Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same
KR20070068460A (ko) 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
WO2007008780A2 (en) 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
CA2638815A1 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
US20100055069A1 (en) 2006-04-21 2010-03-04 Transgene S.A. Hpv-18-based papillomavirus vaccines
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US20150182621A1 (en) 2009-04-28 2015-07-02 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
RU2578420C2 (ru) 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
WO2012106490A1 (en) * 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
WO2013116778A2 (en) 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
AU2014340201B2 (en) 2013-10-23 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015127027A1 (en) 2014-02-20 2015-08-27 Wayne State University Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US20170196953A1 (en) 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006479A2 (en) * 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
WO2014031178A1 (en) * 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY LETTERS, vol. 122, JPN6019050596, 2009, pages 44 - 51, ISSN: 0004264997 *
VACCINE, vol. 29, JPN6019050592, 2011, pages 304 - 313, ISSN: 0004264995 *
VACCINE, vol. 29, JPN6019050594, 2011, pages 7020 - 7026, ISSN: 0004264996 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023527261A (ja) * 2020-03-11 2023-06-28 イミュニティーバイオ、インコーポレイテッド Ｃｏｖｉｄ－１９の治療及びその方法
JP7692925B2 (ja) 2020-03-11 2025-06-16 ナントセル，インコーポレイテッド Ｃｏｖｉｄ－１９の治療及びその方法

Also Published As

Publication number Publication date
EP3256140A1 (en) 2017-12-20
ES2795833T3 (es) 2020-11-24
WO2016112188A1 (en) 2016-07-14
EP3256140B1 (en) 2020-04-01
KR20170102002A (ko) 2017-09-06
EP3256140A4 (en) 2018-07-18
CN107530383A (zh) 2018-01-02
AU2016205208A1 (en) 2017-07-06
US10695417B2 (en) 2020-06-30
CA2973109A1 (en) 2016-07-14
US20170368161A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
EP3256140B1 (en) Compositions for ebola virus vaccination
CN113456812B (zh) 用于联合免疫治疗的方法和组合物
US10563224B2 (en) Replication defective adenovirus vector in vaccination
KR20220016137A (ko) 변형된 아데노바이러스
KR20210013589A (ko) 면역 체크포인트 억제제 공동-발현 벡터
US20180344832A1 (en) Methods and compositions for combination immunotherapy
KR20210090650A (ko) 알파바이러스 신생항원 벡터 및 인터페론 억제제
AU2017353443B2 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
JP2018524977A (ja) アデノウイルスポリヌクレオチド及びポリペプチド
CN110831620A (zh) 包含il-15超激动剂的联合免疫疗法
KR20220041844A (ko) Hiv 항원 및 mhc 복합체
KR20230006825A (ko) 전염성 질병 항원 및 백신
CN111836639A (zh) 用于联合癌症疫苗和免疫辅助疗法的组合物和方法
AU2024205755A1 (en) Treatment of covid-19 and methods therefor
KR20230014694A (ko) 항원-코딩 카세트
CN114828878A (zh) 用于癌症治疗的载体
JP2021535730A (ja) 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用
US20070264281A1 (en) Vaccination Vectors Derived From Lymphotropic Human Herpes Viruses 6 and 7
KR20230026980A (ko) 항-gucy2c 백신 및 백신접종

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200520